keyword
https://read.qxmd.com/read/38517886/evolution-of-chromosome-arm-aberrations-in-breast-cancer-through-genetic-network-rewiring
#21
JOURNAL ARTICLE
Elena Kuzmin, Toby M Baker, Tom Lesluyes, Jean Monlong, Kento T Abe, Paula P Coelho, Michael Schwartz, Joseph Del Corpo, Dongmei Zou, Genevieve Morin, Alain Pacis, Yang Yang, Constanza Martinez, Jarrett Barber, Hellen Kuasne, Rui Li, Mathieu Bourgey, Anne-Marie Fortier, Peter G Davison, Atilla Omeroglu, Marie-Christine Guiot, Quaid Morris, Claudia L Kleinman, Sidong Huang, Anne-Claude Gingras, Jiannis Ragoussis, Guillaume Bourque, Peter Van Loo, Morag Park
The basal breast cancer subtype is enriched for triple-negative breast cancer (TNBC) and displays consistent large chromosomal deletions. Here, we characterize evolution and maintenance of chromosome 4p (chr4p) loss in basal breast cancer. Analysis of The Cancer Genome Atlas data shows recurrent deletion of chr4p in basal breast cancer. Phylogenetic analysis of a panel of 23 primary tumor/patient-derived xenograft basal breast cancers reveals early evolution of chr4p deletion. Mechanistically we show that chr4p loss is associated with enhanced proliferation...
March 21, 2024: Cell Reports
https://read.qxmd.com/read/38516826/sbfi26-induces-triple-negative-breast-cancer-cells-ferroptosis-via-lipid-peroxidation
#22
JOURNAL ARTICLE
Gang He, Yiyuan Zhang, Yanjiao Feng, Tangcong Chen, Mei Liu, Yue Zeng, Xiaojing Yin, Shaokui Qu, Lifen Huang, Youqiang Ke, Li Liang, Jun Yan, Wei Liu
SBFI26, an inhibitor of FABP5, has been shown to suppress the proliferation and metastasis of tumour cells. However, the underlying mechanism by which SBFI26 induces ferroptosis in breast cancer cells remains largely unknown. Three breast cancer cell lines were treated with SBFI26 and CCK-8 assessed cytotoxicity. Transcriptome was performed on the Illumina platform and verified by qPCR. Western blot evaluated protein levels. Malondialdehyde (MDA), total superoxide dismutase (T-SOD), Fe, glutathione (GSH) and oxidized glutathione (GSSG) were measured...
April 2024: Journal of Cellular and Molecular Medicine
https://read.qxmd.com/read/38516703/integrated-network-pharmacology-and-experimental-verification-to-explore-the-potential-mechanism-of-san-ying-decoction-for-treating-triple-negative-breast-cancer
#23
JOURNAL ARTICLE
Xiaojuan Yang, Feifei Li, Youyang Shi, Yuanyuan Wu, Rui Yang, Xiaofei Liu, Yang Zhang, Guangtao Zhang, Mei Ma, Zhanyang Luo, Xianghui Han, Ying Xie, Sheng Liu
Traditional Chinese medicine (TCM) has been used to treat triple-negative breast cancer (TNBC), a breast cancer subtype with poor prognosis. Clinical studies have verified that the Sanyingfang formula (SYF), a TCM prescription, has obvious effects on inhibiting breast cancer recurrence and metastasis, prolonging patient survival, and reducing clinical symptoms. However, its active ingredients and molecular mechanisms are still unclear. In this study, the active ingredients of each herbal medicine composing SYF and their target proteins are obtained from the Traditional Chinese Medicine Systems Pharmacology database...
March 21, 2024: Acta Biochimica et Biophysica Sinica
https://read.qxmd.com/read/38514799/starfysh-integrates-spatial-transcriptomic-and-histologic-data-to-reveal-heterogeneous-tumor-immune-hubs
#24
JOURNAL ARTICLE
Siyu He, Yinuo Jin, Achille Nazaret, Lingting Shi, Xueer Chen, Sham Rampersaud, Bahawar S Dhillon, Izabella Valdez, Lauren E Friend, Joy Linyue Fan, Cameron Y Park, Rachel L Mintz, Yeh-Hsing Lao, David Carrera, Kaylee W Fang, Kaleem Mehdi, Madeline Rohde, José L McFaline-Figueroa, David Blei, Kam W Leong, Alexander Y Rudensky, George Plitas, Elham Azizi
Spatially resolved gene expression profiling provides insight into tissue organization and cell-cell crosstalk; however, sequencing-based spatial transcriptomics (ST) lacks single-cell resolution. Current ST analysis methods require single-cell RNA sequencing data as a reference for rigorous interpretation of cell states, mostly do not use associated histology images and are not capable of inferring shared neighborhoods across multiple tissues. Here we present Starfysh, a computational toolbox using a deep generative model that incorporates archetypal analysis and any known cell type markers to characterize known or new tissue-specific cell states without a single-cell reference...
March 21, 2024: Nature Biotechnology
https://read.qxmd.com/read/38514650/mir-218-5p-and-doxorubicin-combination-enhances-anticancer-activity-in-breast-cancer-cells-through-parkin-dependent-mitophagy-inhibition
#25
JOURNAL ARTICLE
Francesco Davide Naso, Krenare Bruqi, Valeria Manzini, Valerio Chiurchiù, Mara D'Onofrio, Ivan Arisi, Flavie Strappazzon
Breast Cancer (BC) is one of the most common tumours, and is known for its ability to develop resistance to chemotherapeutic treatments. Autophagy has been linked to chemotherapeutic response in several types of cancer, highlighting its contribution to this process. However, the role of mitophagy, a selective form of autophagy responsible for damaged mitochondria degradation, in the response to therapies in BC is still unclear. In order to address this point, we analysed the role of mitophagy in the treatment of the most common anticancer drug, doxorubicin (DXR), in different models of BC, such as a luminal A subtype-BC cell line MCF7 cells, cultured in 2-Dimension (2D) or in 3-Dimension (3D), and the triple negative BC (TNBC) cell line MDA-MB-231...
March 21, 2024: Cell Death Discovery
https://read.qxmd.com/read/38513728/spatiotemporally-controlled-hydrophobic-drug-delivery-via-photosensitizer-driven-assembly-disassembly-for-enhanced-triple-negative-breast-cancer-treatment
#26
JOURNAL ARTICLE
Fanhui Kong, Peiying He, Jiani Jiang, Wei Zhu, Qi Lei
Therapeutic approaches for triple-negative breast cancer (TNBC) have been continuously advancing, but inadequate control over release behavior, insufficient tumor selectivity, and limited drug availability continue to impede therapeutic outcomes in nanodrug systems. In this study, we propose a general hydrophobic antineoplastic delivery system, termed spatiotemporally-controlled hydrophobic antineoplastic delivery system (SCHADS) for enhanced TNBC treatment. The key feature of SCHADS is the formation of metastable photosensitive-antineoplastic complexes (PACs) through the self-assembly of hydrophobic drugs driven by photosensitive molecules...
March 19, 2024: Journal of Controlled Release
https://read.qxmd.com/read/38513466/assessing-the-relationship-between-tumor-infiltrating-lymphocytes-and-pd-l1-expression-in-triple-negative-breast-cancer-identifying-optimal-tils-cut-off-value-for-pathologic-reporting
#27
JOURNAL ARTICLE
Krit Suwannaphoom, Sithapong Soontornsit, Kulachet Wiwatwarayos, Prapapun Seneetuntigul, Parsinee Julimasart
BACKGROUND: Triple Negative Breast Cancer (TNBC) presents diagnostic complexities, particularly in evaluating Tumor-Infiltrating Lymphocytes (TILs) and Programmed Death-Ligand 1 (PD-L1) expression. This study aimed to identify optimal TILs percentage cut-offs predictive of PD-L1 expression and to investigate the relationship between TILs, PD-L1, and tertiary lymphoid structures (TLSs). METHOD: Method: Analyzing 141 TNBC cases, we assessed TILs, PD-L1 expression (clones 22C3 and SP142), and TLS presence...
March 16, 2024: Annals of Diagnostic Pathology
https://read.qxmd.com/read/38513102/activation-of-er%C3%AE-hijacks-the-splicing-machinery-to-trigger-r-loop-formation-in-triple-negative-breast-cancer
#28
JOURNAL ARTICLE
Dongfang Wang, Muya Tang, Peidong Zhang, Kailin Yang, Liang Huang, Mengrui Wu, Qiuhong Shen, Jing Yue, Wei Wang, Yanqiu Gong, Margaret Warner, Lunzhi Dai, Haihuai He, Zhengnan Yang, Jan-Ake Gustafsson, Shengtao Zhou
Triple-negative breast cancer (TNBC) is a subtype of breast cancer with aggressive behavior and poor prognosis. Current therapeutic options available for TNBC patients are primarily chemotherapy. With our evolving understanding of this disease, novel targeted therapies, including poly ADP-ribose polymerase (PARP) inhibitors, antibody-drug conjugates, and immune-checkpoint inhibitors, have been developed for clinical use. Previous reports have demonstrated the essential role of estrogen receptor β (ERβ) in TNBC, but the detailed molecular mechanisms downstream ERβ activation in TNBC are still far from elucidated...
March 26, 2024: Proceedings of the National Academy of Sciences of the United States of America
https://read.qxmd.com/read/38512527/identification-and-validation-of-neutrophils-related-subtypes-and-prognosis-model-in-triple-negative-breast-cancer
#29
JOURNAL ARTICLE
Shanqi Li, Yuzhou Qian, Wanchen Xie, Xinyu Li, Jiaying Wei, Long Wang, Guosheng Ren, Xuedong Yin
BACKGROUND: Neutrophils are considered to be crucial players in the initiation and progression of cancer. However, the complex relationship between neutrophils and cancer prognosis remains elusive, mainly due to the significant plasticity and diversity exhibited by these immune cells. METHODS: As part of our thorough investigation, we examined 38 Neutrophils-Related Genes (NRGs) and the associated copy number variations (CNV), somatic mutations, and gene expression patterns in relation to triple negative breast cancer (TNBC)...
March 21, 2024: Journal of Cancer Research and Clinical Oncology
https://read.qxmd.com/read/38512047/exploring-the-phototoxicity-of-gsh-resistant-2-5-6-dichloro-1-h-benzo-d-imidazol-2-yl-quinoline-based-ir-iii-pta-complexes-in-mda-mb-231-cancer-cells
#30
JOURNAL ARTICLE
Utpal Das, Priyankar Paira
Metal complexes play a crucial role in photo-activated chemotherapy (PACT), which has recently been used to treat specific disorders. Triple-negative breast cancer has an enormously high rate of relapse due to the existence and survival of cancer stem cells (CSCs) characterized by increased amounts of glutathione (GSH). Hence, designing a phototoxic molecule is an enticing area of research to combat triple-negative breast cancer (TNBC) via GSH depletion and DNA photocleavage. Herein, we focus on the application of PTA and non-PTA Ir(III) complexes for phototoxicity in the absence and presence of GSH against MDA-MB-231 TNBC cells...
March 21, 2024: Dalton Transactions: An International Journal of Inorganic Chemistry
https://read.qxmd.com/read/38511030/is-ki-67-really-useful-as-a-predictor-for-response-to-neoadjuvant-chemotherapy-in-locally-advanced-breast-cancer
#31
JOURNAL ARTICLE
Sukruti Dave, Arpan Choudhury, Shirish S Alurkar, Akash M Shah
Neoadjuvant chemotherapy (NACT) is routinely offered to operable locally advanced breast cancer (LABC) patients desirous of breast conservation surgery and inoperable LABC patients. Pathological complete response (pCR) following chemotherapy is recognized as a surrogate for survival outcomes in high grade tumour subtypes. Many biological and tumor characters have been shown to predict pCR. The current study was performed with the aim of investigating the ability of Ki-67 in predicting pCR with NACT in breast cancer patients...
March 2024: Indian Journal of Surgical Oncology
https://read.qxmd.com/read/38510127/%C3%AE-np63-regulates-mdsc-survival-and-metabolism-in-triple-negative-breast-cancer
#32
JOURNAL ARTICLE
Ukjin Kim, Rahul Debnath, Javier E Maiz, Joshua Rico, Satrajit Sinha, Mario Andrés Blanco, Rumela Chakrabarti
Triple-negative breast cancer (TNBC) contributes greatly to mortality of breast cancer, demanding new targetable options. We have shown that TNBC patients have high ΔNp63 expression in tumors. However, the function of ΔNp63 in established TNBC is yet to be explored. In current studies, targeting ΔNp63 with inducible CRISPR knockout and Histone deacetylase inhibitor Quisinostat showed that ΔNp63 is important for tumor progression and metastasis in established tumors by promoting myeloid-derived suppressor cell (MDSC) survival through tumor necrosis factor alpha...
April 19, 2024: IScience
https://read.qxmd.com/read/38507019/stk32c-modulates-doxorubicin-resistance-in-triple-negative-breast-cancer-cells-via-glycolysis-regulation
#33
JOURNAL ARTICLE
Huawei Xiao, Lei Liu, Shaoyan Huang
Understanding the mechanisms underlying doxorubicin resistance in triple-negative breast cancer (TNBC) holds paramount clinical significance. In our study, we investigate the potential of STK32C, a little-explored kinase, to impact doxorubicin sensitivity in TNBC cells. Our findings reveal elevated STK32C expression in TNBC specimens, associated with unfavorable prognosis in doxorubicin-treated TNBC patients. Subsequent experiments highlighted that STK32C depletion significantly augmented the sensitivity of doxorubicin-resistant TNBC cells to doxorubicin...
March 20, 2024: Molecular and Cellular Biochemistry
https://read.qxmd.com/read/38505617/immunotherapeutic-il-6r-and-targeting-the-mct-1-il-6-cxcl7-pd-l1-circuit-prevent-relapse-and-metastasis-of-triple-negative-breast-cancer
#34
JOURNAL ARTICLE
Aushia Tanzih Al Haq, Pao-Pao Yang, Christopher Jin, Jou-Ho Shih, Li-Mei Chen, Hong-Yu Tseng, Yen-An Chen, Yueh-Shan Weng, Lu-Hai Wang, Michael P Snyder, Hsin-Ling Hsu
Rationale: Multiple copies in T-cell malignancy 1 (MCT-1) is a prognostic biomarker for aggressive breast cancers. Overexpressed MCT-1 stimulates the IL-6/IL-6R/gp130/STAT3 axis, which promotes epithelial-to-mesenchymal transition and cancer stemness. Because cancer stemness largely contributes to the tumor metastasis and recurrence, we aimed to identify whether the blockade of MCT-1 and IL-6R can render these effects and to understand the underlying mechanisms that govern the process. Methods: We assessed primary tumor invasion, postsurgical local recurrence and distant metastasis in orthotopic syngeneic mice given the indicated immunotherapy and MCT-1 silencing (shMCT-1)...
2024: Theranostics
https://read.qxmd.com/read/38503397/multifunctional-iron-apigenin-nanocomplex-conducting-photothermal-therapy-and-triggering-augmented-immune-response-for-triple-negative-breast-cancer
#35
JOURNAL ARTICLE
Ruijie Chen, Zewei Jiang, Yingfeng Cheng, Jinyao Ye, Shize Li, Yitianhe Xu, Zhanzheng Ye, Yifan Shi, Jie Ding, Yingyi Zhao, Hailun Zheng, Fugen Wu, Guangyong Lin, Congying Xie, Qing Yao, Longfa Kou
Triple negative breast cancer (TNBC) presents a formidable challenge due to its low sensitivity to many chemotherapeutic drugs and a relatively low overall survival rate in clinical practice. Photothermal therapy has recently garnered substantial interest in cancer treatment, owing to its swift therapeutic effectiveness and minimal impact on normal cells. Metal-polyphenol nanostructures have recently garnered significant attention as photothermal transduction agents due to their facile preparation and favorable photothermal properties...
March 17, 2024: International Journal of Pharmaceutics
https://read.qxmd.com/read/38502995/clinical-management-monitoring-and-prophylaxis-of-adverse-events-of-special-interest-associated-with-datopotamab-deruxtecan
#36
REVIEW
Rebecca S Heist, Jacob Sands, Aditya Bardia, Toshio Shimizu, Aaron Lisberg, Ian Krop, Noboru Yamamoto, Takahiro Kogawa, Saba Al-Hashimi, Simon S M Fung, Anat Galor, Francesca Pisetzky, Priyanka Basak, Cindy Lau, Funda Meric-Bernstam
Antibody drug conjugates (ADCs) are an emerging class of treatments designed to improve efficacy and decrease toxicity compared with other systemic therapies through the selective delivery of cytotoxic agents to tumor cells. Datopotamab deruxtecan (Dato-DXd) is a novel ADC comprising a topoisomerase I inhibitor payload and a monoclonal antibody directed to trophoblast cell-surface antigen 2 (TROP2), a protein that is broadly expressed in several types of solid tumors. Dato-DXd is being investigated across multiple solid tumor indications...
March 11, 2024: Cancer Treatment Reviews
https://read.qxmd.com/read/38502228/evaluating-immunotherapeutic-outcomes-in-triple-negative-breast-cancer-with-a-cholesterol-radiotracer-in-mice
#37
JOURNAL ARTICLE
Nicholas G Ciavattone, Jenny Nan Guan, Alex Farfel, Jenelle Stauff, Timothy J Desmond, Benjamin L Viglianti, Peter Jh Scott, Allen F Brooks, Gary D Luker
Evaluating the response to immune checkpoint inhibitors (ICIs) remains an unmet challenge in triple-negative breast cancer (TNBC). The requirement of cholesterol for activation and function of T cells led us to hypothesize that quantifying cellular accumulation of this molecule could distinguish successful from ineffective checkpoint immunotherapy. To analyze accumulation of cholesterol by T cells in the immune microenvironment of breast cancer, we leveraged the PET radiotracer, eFNP-59. eFNP-59 is an analog of cholesterol that our group validated as an imaging biomarker for cholesterol uptake in pre-clinical models and initial human studies...
March 19, 2024: JCI Insight
https://read.qxmd.com/read/38502143/radiation-therapy-for-triple-negative-breast-cancer-from-molecular-insights-to-clinical-perspectives
#38
REVIEW
Jongmyung Kim, Veronia Fahmy, Bruce G Haffty
INTRODUCTION: Triple-negative breast cancer (TNBC) lacks three common receptors, making traditional treatments less effective. This review highlights the importance of radiotherapy and emerging therapeutic strategies to enhance treatment outcomes in TNBC. AREAS COVERED: We conducted a literature search on PubMed for publications from 2000 to 2023 to discuss the critical role of radiotherapy in managing TNBC, emphasizing its applications from locoregional control to improving survival rates...
March 19, 2024: Expert Review of Anticancer Therapy
https://read.qxmd.com/read/38501542/obesity-correlates-with-the-immunosuppressive-ilc2s-mdscs-axis-in-advanced-breast-cancer
#39
JOURNAL ARTICLE
Wei Liu, Bingyu Li, Dan Liu, Bing Zhao, Gang Sun, Jianbing Ding
AIM: We investigated the relationship between the group 2 innate lymphoid cells (ILC2s)-myeloid-derived suppressor cells (MDSCs) axis and obesity-related breast cancer. METHODS: Fifty-eight patients with breast cancer who had first relapse and metastasis between January 2019 and August 2021 were enrolled. The proportions of ILC2s and MDSCs in blood and the levels of cytokines in serum were detected with flow cytometry. Correlation analysis among clinical characteristics (such as body mass index [BMI]), cytokines, ILC2s, and MDSCs was conducted...
March 2024: Immunity, Inflammation and Disease
https://read.qxmd.com/read/38501219/a-phase-ib-study-evaluating-the-recommended-phase-ii-dose-safety-tolerability-and-efficacy-of-mivavotinib-in-combination-with-nivolumab-in-advanced-solid-tumors
#40
JOURNAL ARTICLE
Dejan Juric, Minal Barve, Ulka Vaishampayan, Desamparados Roda, Aitana Calvo, Noelia Martinez Jañez, Jose Trigo, Alastair Greystoke, R Donald Harvey, Anthony J Olszanski, Mateusz Opyrchal, Alexander Spira, Fiona Thistlethwaite, Begoña Jiménez, Jessica Huck Sappal, Karuppiah Kannan, Jason Riley, Cheryl Li, Cong Li, Richard C Gregory, Harry Miao, Shining Wang
Mivavotinib (TAK-659/CB-659), a dual SYK/FLT3 inhibitor, reduced immunosuppressive immune cell populations and suppressed tumor growth in combination with anti-PD-1 therapy in cancer models. This dose-escalation/expansion study investigated the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of mivavotinib plus nivolumab in patients with advanced solid tumors. Patients received oral mivavotinib 60-100 mg once-daily plus intravenous nivolumab 3 mg/kg on days 1 and 15 in 28-day cycles until disease progression or unacceptable toxicity...
March 2024: Cancer Medicine
keyword
keyword
23272
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.